Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.
Discovery of breakthrough antibiotic compounds
27 September 2016
Redx Pharma Plc announces the discovery of a series of compounds that have the potential to create the first novel class of broad-spectrum antibiotics in 30 years.
As previously announced, Redx scientists have identified novel bacterial topoisomerase inhibitors that work as antibiotics against drug resistant Gram-negative bacteria. In vivo testing has now confirmed that Redx has discovered a series of compounds that are highly effective against drug resistant strains of Gram-negative bacteria. This could have important implications for drug resistant infections such as E. coli and Pseudomonas, which are responsible for critical illnesses such as pneumonia, blood poisoning, and urinary tract and abdominal infections.
In the pre-clinical study, Redx achieved a significant decrease in bacterial infection levels against a multi-drug resistant Gram-negative bacterial strain when compared with tigecycline, a current drug-of-last-resort used in treating antibiotic resistant bacteria.
Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.
Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.
Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.